Nothing Special   »   [go: up one dir, main page]

BRPI0716445A2 - composiÇço farmacÊutica - Google Patents

composiÇço farmacÊutica

Info

Publication number
BRPI0716445A2
BRPI0716445A2 BRPI0716445-9A2A BRPI0716445A BRPI0716445A2 BR PI0716445 A2 BRPI0716445 A2 BR PI0716445A2 BR PI0716445 A BRPI0716445 A BR PI0716445A BR PI0716445 A2 BRPI0716445 A2 BR PI0716445A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BRPI0716445-9A2A
Other languages
English (en)
Inventor
Bertil Abrahamsson
Jonas Oedman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0716445A2 publication Critical patent/BRPI0716445A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0716445-9A2A 2006-09-05 2007-09-04 composiÇço farmacÊutica BRPI0716445A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84243206P 2006-09-05 2006-09-05
PCT/SE2007/000771 WO2008030161A1 (en) 2006-09-05 2007-09-04 Pharmaceutical composition comprising candesartan cilexetil

Publications (1)

Publication Number Publication Date
BRPI0716445A2 true BRPI0716445A2 (pt) 2013-09-17

Family

ID=39157499

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716445-9A2A BRPI0716445A2 (pt) 2006-09-05 2007-09-04 composiÇço farmacÊutica

Country Status (12)

Country Link
US (1) US20080058399A1 (pt)
EP (1) EP2063888A4 (pt)
JP (1) JP2010502698A (pt)
KR (1) KR20090049089A (pt)
CN (1) CN101528224A (pt)
AU (1) AU2007293727A1 (pt)
BR (1) BRPI0716445A2 (pt)
CA (1) CA2662040A1 (pt)
IL (1) IL197093A0 (pt)
MX (1) MX2009002425A (pt)
NO (1) NO20090797L (pt)
WO (1) WO2008030161A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070249694A1 (en) * 2005-12-29 2007-10-25 Azaria Caroline A Metaxalone formulations and methods for the preparation thereof
KR20090130325A (ko) * 2007-04-25 2009-12-22 테바 파마슈티컬 인더스트리즈 리미티드 약학 부형제 복합체
EP2182927A2 (en) * 2007-08-01 2010-05-12 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of candesartan
DE102007052070A1 (de) * 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Candesartancilexetil
EP2106789A1 (en) * 2008-03-31 2009-10-07 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising candesartan
CN101862325B (zh) * 2009-04-20 2013-12-04 北京德众万全药物技术开发有限公司 一种含有坎地沙坦酯的药物组合物
HUP0900384A2 (en) * 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate olmesartan medoxomil compositions
HUP0900376A2 (en) 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate candesartan cilexetil composition
CZ302789B6 (cs) * 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
US8399501B2 (en) * 2010-03-04 2013-03-19 Theravance, Inc. Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof
JP2012051829A (ja) * 2010-08-31 2012-03-15 Taiyo Yakuhin Kogyo Kk 安定なアンジオテンシii受容体拮抗作用を示す薬物製剤の設計
JP5756651B2 (ja) * 2011-02-24 2015-07-29 エルメッド エーザイ株式会社 カンデサルタンシレキセチルを安定化した組成物及びその製造方法
JP2013067574A (ja) * 2011-09-21 2013-04-18 Teva Pharma Japan Inc 安定化された医薬組成物
WO2014010008A1 (ja) * 2012-07-09 2014-01-16 東洋カプセル株式会社 カンデサルタンシレキセチルのカプセル充填用組成物
CN102885810B (zh) * 2012-10-30 2015-08-05 台州职业技术学院 一种坎地沙坦酯双释胶囊及其制备方法
JP6379043B2 (ja) 2013-01-30 2018-08-22 沢井製薬株式会社 カンデサルタンシレキセチル含有医薬組成物
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100634953B1 (ko) * 1998-07-20 2006-10-17 스미스클라인 비참 코포레이션 에프로사르탄을 포함하는 생물학적으로 강화된 경구 고형투여 형태의 제제
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
WO2002030400A1 (fr) * 2000-10-06 2002-04-18 Takeda Chemical Industries, Ltd. Preparations solides
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
WO2005070398A2 (en) * 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
WO2005079751A2 (en) * 2004-01-23 2005-09-01 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of candesartan cilexetil
EP1713795A2 (en) * 2004-02-11 2006-10-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
WO2005123721A2 (en) * 2004-06-18 2005-12-29 Ranbaxy Laboratories Limited Amorphous and polymorphic forms of candesartan cilexetil
EP1655298A1 (en) * 2004-11-03 2006-05-10 LEK Pharmaceuticals d.d. Novel polymorph forms of candesartan cilexetil
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
US20060111417A1 (en) * 2004-11-23 2006-05-25 Purandhar Koilkonda Amorphous telmisartan
EA200701442A1 (ru) * 2005-01-06 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиции наночастиц кандесартана
KR20080042039A (ko) * 2005-04-18 2008-05-14 루비콘 리서치 피브이티. 엘티디. 생물학적으로 강화된 조성물

Also Published As

Publication number Publication date
KR20090049089A (ko) 2009-05-15
CN101528224A (zh) 2009-09-09
WO2008030161A1 (en) 2008-03-13
EP2063888A1 (en) 2009-06-03
AU2007293727A1 (en) 2008-03-13
NO20090797L (no) 2009-03-19
JP2010502698A (ja) 2010-01-28
US20080058399A1 (en) 2008-03-06
MX2009002425A (es) 2009-03-20
IL197093A0 (en) 2009-11-18
CA2662040A1 (en) 2008-03-13
EP2063888A4 (en) 2009-11-04

Similar Documents

Publication Publication Date Title
LTC2140867I2 (lt) Farmacinė kompozicija
LTPA2018014I1 (lt) Farmacinė kompozicija 514
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0719393A2 (pt) Composição farmacêutica
BRPI0721651A2 (pt) Composição farmacêutica
DK2041139T3 (da) Farmaceutiske forbindelser
RU2398586C3 (ru) Фармацевтическая композиция
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0716325A2 (pt) Composição antimicrobianas
RU2493831C3 (ru) Фармацевтические композиции
FR2899479B1 (fr) Composition cicatrisante
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
BRPI0810928A2 (pt) "composição farmacêutica"
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
DK1984009T3 (da) Farmaceutiske sammensætninger med forbedret stabilitet
DK2120884T3 (da) Farmaceutisk sammensætning
DK1986650T3 (da) Manipulationssikre doserignsformer
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI0716458A2 (pt) Composição de vulcanizado
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
BRPI0817833A2 (pt) Composição farmacêutica antimalárica
BRPI0921313A2 (pt) composição farmaucêutica
BRPI0820198A2 (pt) composições farmacêuticas
BRPI0912171A2 (pt) composição farmacêutica

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 5A, 6A E 7A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.